Image

Dynamic Blood Inflammatory Profile in Atopic Dermatitis Patients (ADAMUNE)

Dynamic Blood Inflammatory Profile in Atopic Dermatitis Patients (ADAMUNE)

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

This is a prospective, single-center, class 2 study to better characterize the immune response in immune response in the blood of atopic dermatitis. Investigators are following in the referral center of Nice, 100 patients with atopic dermatitis. Investigators plan to include 30 patients. Blood samples will be collected to assess cytokine levels after non-specific immune stimulation. immune stimulation. Whole blood will be collected and stimulated with immune ligands (anti-CD3 T-cell stimulating ligands associated with Thymic Stromal LymphoPoietin (TSLP) or TLR agonist R848 7/8 agonist stimulating NK (natural killer) lymphocytes and promoting T cell response) on lyophilized freeze-dried spheres (LyoSphere, Qiagen) within 8 hours of blood collection.

Eligibility

Inclusion Criteria:

  • Patient aged ≥ 18 years.
  • Patient with clinically diagnosed atopic dermatitis according to the criteria of Hanifin and Rajka.
  • Moderate to severe defined by an Investigator's Global Assessment ³3 and eligible to systemic treatment.
  • If the subject is a woman of childbearing potential, she has a negative urine pregnancy test.
  • Subject is non-pregnant, non-lactating and is not planning for pregnancy during the study period.
  • Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair his/her evaluation or which exposes the subject to an unacceptable risk by study participation.
  • Subject is able to comprehend and willing to sign an Informed Consent and/or Assent Form.
  • Affiliation to a social security scheme.
  • Signed informed consent

Exclusion Criteria:

  • Vulnerable person: pregnant or nursing woman, minor, adult under guardianship or deprived of liberty
  • Patient with an infection
  • Patient with other systemic inflammatory disease
  • Patient with anti-inflammatory or immunosuppressive therapy
  • Patient with a contraindication to JAK inhibitors
  • Participants in other clinical therapeutic studies involving a drug that may interfere with the present evaluation

Study details
    Atopic Dermatitis

NCT05868824

Centre Hospitalier Universitaire de Nice

9 June 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.